Compare Abbott Laboratories (ABT) vs Baidu Inc (BIDU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Baidu Inc — how do they compare? Abbott Laboratories trades at $110.05 (market cap $187.95B), while Baidu Inc trades at $103.86 (market cap $36.18B). The key difference: Abbott Laboratories is far larger — about 5.2× Baidu Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Baidu Inc pays none. Which is the better fit depends on your goals.
| ABT | BIDU | |
|---|---|---|
Market Cap | $187.95B | $36.18B |
Sector | Health | Media |
52-Week High | $136.62 | $162.52 |
52-Week Low | $82.57 | $86.76 |
Enterprise Value | $214.96B | $32.81B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Baidu (BIDU) trades at $109.50, down 0.19% on the day, with technicals indicating a bearish trend and key support at $108. The company reported a sharp decline in net income to $5.59 billion in 2025, with margins contracting, though it beat EPS estimates in two of the last three quarters. Recent news highlights autonomous vehicle testing in London and a planned Q2 2026 earnings report on August 18, 2026.
The outlook is mixed: strong analyst buy ratings (75.47%) and a $169.80 price target suggest upside, but bearish technicals, profit margin pressures, and China market risks pose challenges. Investment opportunity hinges on AI and cloud growth offsetting advertising weakness, while risks include execution missteps and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →
